Introduction
The diagnosis and treatment of intercurrent illnesses is the first concern in the medical management of the Human Immunodeficiency Virus (HIV). Thereafter the need for prophylactic therapy needs to be assessed. The latter is dealt with in the next issue.
Only the opportunistic infections (OIs) seen most commonly will be dealt with. The medication dosages and expected response times are summarised in Table I . Only drugs available in South Africa, are suggested. Some of the OIs decrease quality of life, without being lifethreatening, while others are immediately life-threatening. All should be treated as quickly and effectively as possible. Treatment with highly active antiretrovirals (HAART) is the best method to prevent OIs in persons with immune suppression due to HIV.
ORAL CANDIDIASIS
Clinical presentation HIV infection is associated with a variety of oral lesions and oral manifestations are often the first clinical expression of HIV infection in an individual. 1, 2 Oral candidiasis is a useful marker for immune deterioration and is a predictor of full-blown Acquired Immunodeficiency Syndrome (AIDS) in adults. 3 The infection is recurrent and becomes progressively severe as the immune system deteriorates.
One of the earliest symptoms is loss of taste sensation, which has to be elicited. Thereafter follows a burning sensation, pain and later difficulty in eating. Oral and oesophageal candidiasis is not life threatening, but can be severely debilitating. The clinical classification of oral candidiasis appears in Table  II and the diagnosis is made on clinical appearance (Figure 1a -c).
Special investigations
Refractory cases of oral candidiasis can be cultured, but this is not done routinely.
Treatment
Topical treatment, and not systemic, is the route of choice. 4 Since the drugs work topically, the target is to allow adequate contact time between the drug and the mucous The management of opportunistic infections and cancer in HIV disease Fever usually abates within 1-2 weeks. Sputa usually become culture negative within 2 months.
Be aware of the immune reconstitution inflammatory syndrome.
Prognosis is poor and response is slow: 2-4 weeks. Mortality at 6 months is 60%.
Good, provided that treatment is started early. Postherpetic pain may continue months.
Good, provided that treatment is started early (within 24 hours of onset).
Poor, high mortality.
Usually resolves spontaneously if CD4 > 100
Responds usually within several days
Response in 4 weeks
Quick response 
ORAL HAIRY LEUKOPLAKIA

Clinical presentation
Hairy leukoplakia predicts a rapid progression from HIV to AIDS. 5 It occurs on the lateral borders of the tongue and is a white keratotic lesion that cannot by scraped off with a spatula. Often there are vertical striations, giving it the characteristic "hairy" appearance. Although most-ly asymptomatic, the lesions can sometimes cause discomfort.
Treatment
Acyclovir can be used for severe cases, but this treatment is usually not indicated. These lesions improve when the patient starts HAART.
HIV-ASSOCIATED PERIO-DONTAL DISEASE
Clinical presentation
Periodontitis and gingivitis are observed in all stages of HIV. 6 Acute necrotising ulcerative gingivitis (ANUG) is a severe form of gingivitis. The patient usually complains of painful or bleeding gums.
Treatment
For acute cases amoxicillin and metronidazole may be used for 5 days. Chlorhexidine gluconate 0.2% mouthwash is also indicated for long-term use. Oral hygiene is important. Cleaning and scaling of teeth should also be done to remove plaque and calculus. 7 
CANDIDA OESOPHAGITIS
Clinical presentation
The patient experiences dysphagia, first for solid foods, and as the disease progresses, also for fluids. Presenting symptoms may also be vomiting, dehydration and loss of weight. The clinical diagnosis is suggested by clinical features. In most cases the patient also has oral candidiasis. The CD4 count is usually less than 100 cells/L. Endos-copy is only indicated for an atypical presentation or treatment failure.
The differential diagnoses of dysphagia in HIV include: • Candida oesophagitis • Cytomegalovirus ulceration • Herpes simplex ulceration
Treatment Systemic treatment with an azole is indicated. Itraconazole or fluconazole is effective when given for 14-21 days. Analgesics should be administered in the first few days of treatment. Although relapses are common, prophylactic therapy is not indicated, since it may lead to resistance.
PNEUMOCYSTIS JEROVECI PNEUMONIA (PCP)
Clinical presentation This organism was previously known as Pneumocystis carinii. The onset of the infection is insidious. The main clinical features are progressive dyspnoea and a dry cough developing over 2-3 weeks. Often, the chest examination is unremarkable, except for tachypnoea. This infection is usually associated with a CD4 count below 100 cells/L. 8 
Special investigations
In early cases, up to 20% of chest x-rays can be normal. The classical chest X-ray ( Figure 2 ) shows a symmetrical perihilar interstitial infiltrate. It is also be described as "ground glass". The differential diagnosis of a diffuse reticulonodular infiltrate is listed in Table III .
The arterial blood gasses would show varying degrees of hypoxia. Early disease shows only desaturation during exercise. Lactate dehydrogenase (LDH) is significantly increased in 90% of cases, but it is a nonspecific finding.
Diagnosis is made on sputum induced with nebulised hypertonic saline (positive yield in 60-95%) or bronchoscopy with lavage fluid or transbronchial biopsy (positive yield in 95%). Special stains, silver or immunofluorescence is done on the fluids collected.
Treatment
The treatment choice is high dose co-trimoxazole for three weeks. The alveolar inflammatory response to the infection causes the observed hypoxia. The hypoxia is worsened by initiation of treatment. High dose corticosteroids suppresses the body's inflammatory response and is an essential part of the treatment in any hypoxic patient. 8 In patients allergic to cotrimoxazole, dapsone in combination with trimethoprim may be used, or clindamycin in combination with primaquine. Life-long co-trimoxazole prophylaxis must be instituted after the treatment of the acute infection. The prophylaxis may be stopped if the CD count rises above 200 cells/L in a patient on HAART.
TOXOPLASMA GONDII
Clinical presentation
Toxoplasmosis causes focal neurological signs with a slow onset that can include focal weakness and paresis. It leads to hemiparesis/hemiplegia and confusion follows with a suppressed consciousness. Toxoplasmosis is usually associated with a CD4 count below 100 cells/L.
The differential diagnoses of this clinical picture include: 9 • Lymphoma • Tuberculoma • Cryptococcoma Special investigations A brain scan (Figure 3a,b ) with contrast will reveal multiple ring enhancing lesions with surrounding oedema. Toxoplasma IgG antibodies will be positive. This clinical picture is due to the reactivation of a previous toxoplasma infection. In South Africa, 30-40% of adults in the general population are Toxoplasma IgG positive.
If facilities for a brain scan is not available in a patient with focal neurological signs, the patient should be empirically treated as for toxoplasmosis
Treatment
The active infection is treated with cotrimoxazole for a period of three months. Clindamycin and pyrimethamine is the second-line treatment for patients who cannot tolerate cotrimoxazole. Folinic acid (not folic acid) should be added if pyrimethamine is used, to treat or prevent bone marrow suppression. The patient's response is then monitored clinically.
Thereafter co-trimoxazole should be used as secondary prophylaxis, lifelong or until the CD4 count increases to above 200 cells/L on HAART.
CRYPTOCOCCAL MENINGITIS
Clinical presentation
The most prominent clinical symptom is severe headache. Thereafter the cognitive functioning may change. Confusion follows later. The neurological examination may be normal in a patient presenting early in the disease. The patient will only have meningism late in the disease, and much later, severe neck stiffness and papil oedema. The patient may also be vomiting.
Special examination
A lumbar puncture is immediately indicated. A high cerebrospinal fluid (CSF) pressure is usually present. Repeated lumbar puncture to remove large volumes of CSF (up to 20ml each time) may be necessary to relieve the raised intracranial pressure.
After completion of treatment for the acute infection , the patient should continue prophylactic fluconazole at a lower dosage . This continues lifelong or until the CD4 count increases to above 100 cells/L on HAART. 11
CYTOMEGALOVIRUS (CMV)
Clinical presentation CMV may present as retinitis, encephalitis, pneumonitis or colitis in patients with CD4 count below 50 cells/L. With retinitis the patient presents with floaters, blurring and painless vision loss. CMV retinitis can be diagnosed clinically with fundoscopy (fluffy white lesions and haemorrhages). CMV colitis may cause chronic, often severe and bloody diarrhoea.
Diagnosis
CMV Polymerase Chain Reaction (PCR) can be done on the CSF or pulmonary secretions in cases of encephalitis or pneumonitis. Typical inclusion bodies can be seen on biopsy of the affected organ.
Treatment
Without treatment, CMV retinitis destroys the retina in six months with resultant blindness . Intravitreal ganciclovir is the drug of choice. The aim of treatment would be to protect the vision; damage cannot be reversed. Intravenous treatment of the infection is for 14-21 days, but life-long maintenance therapy is required. Ganciclovir is nephrotoxic. The patient must preferably be referred to an expert for treatment.
MYCOBACTERIUM TUBERCU-LOSIS (TB)
Clinical presentation
Pulmonary tuberculosis (PTB) may present in patients with well preserved to very low CD4 counts and is the most common presentation of M. tuberculosis disease. The presentation is more typical in patients with well preserved CD4 counts, while in patients with very low CD4 counts it can be extremely difficult to confirm a diagnosis of PTB because of the atypical presentation of the disease. Lung examination can be deceptively normal.
Extrapulmonary TB presents most commonly as a large pleural effusion, followed by TB lymphadenitis, miliary TB and TB meningitis. Renal, bone and synovial fluid TB are less frequent. Tuberculous meningitis is a chronic meningitis with a slow onset. With tuberculous lymphadenitis the lymph nodes are usu-ally asymetrically enlarged, matted and painful.
Special investigations
Chest x-ray can be suggestive of TB, but the diagnosis still needs to be confirmed. PTB may present on chest X-ray as typical upper lobe cavities, patchy infiltrates, a miliary picture (Figure 4) or as a normal chest X-ray. The X-ray picture is dependent on the level of immune function present in the host. With TB pericarditis, cardiomegaly is present on chest x-ray ( Figure 5 ).
Diagnosis
Diagnosis is made on sputa, nasogastric aspirations or bronchoscopy with alveolar lavage. In miliary TB, sputum can be positive in 25% of cases. Staining for acid fast bacilli (AFB) should be done on sputum or a lymph node aspirate. PCR for M. tuberculosis can yield quick results, but is more expensive. Culture takes up to a few weeks to yield results. In cases of systemic spread of TB, blood, bone marrow and liver biopsy tissue can be examined for AFB and PCR and culture done on the fluid. Treatment South African National Treatment Guidelines should be followed. The treatment duration for pulmonary TB is the standard short course of 6 months and 9 months for extrapulmonary TB. The intensive phase of treatment consists of isoniazid, pyrazinamide, rifampicin and ethambutol, usually as a combination pill. In the maintenance (continuation) phase isoniazid and rifampicin are used. Direct observed treatment (DOTs) is strongly recommended and offers the patient the best chance of treatment success.
Pyridoxine should be added to avoid treatment-induced peripheral neuropathy.
MYCOBACTERIUM AVIUM COMPLEX (MAC) INFECTION
Clinical presentation Disseminated M. avium disease is usually a very late opportunistic infection with CD4 count of less than 50 cells/mm 3 
Treatment
Combination therapy is used with a macrolide as backbone. The preferred first drug of choice is clarithromycin. The second agent is usually ethambutol, because it is cheap and easy to administer. Critically ill patients may benefit from a third agent, such as rifabutin.
If oral absorption of drugs is problematic, or hepatitis develops, intravenous amikacin may be used. Ciprofloxacin is considered an alternative regimen.
Duration of treatment is indefinite in the absence of HAART and immune reconstitution. However, in patients on antiretrovirals, MAC treatment may be discontinued after one year if the patient is asymptomatic, the CD4 count is above 100 cells/mm 3 for more than 3-6 months and bone marrow and blood cultures are negative. 13 
HERPES ZOSTER
Clinical picture
The diagnosis of shingles is made on clinical grounds -the severe pain and the unilateral vesicular eruptions corresponding to a dermatome innervated by a sensory nerve.
Treatment
An antiviral such as acyclovir, vala-cyclovir or famcyclovir should be used, as long as treatment is initiated within 72 hours of blisters appearing. Therapy shortens the duration of the disease and decreases the incidence and severity of postherpetic pain.
The pain itself can be managed with a nonsteroidal inflammatory for a week, as well as amytriptiline or carbamasepine for a longer period (month or longer).
HERPES SIMPLEX
Clinical picture
Herpes simplex causes mucocutaneous ulceration of the mouth (Figure 6 ), oesophagus, anus and genital area, starting as numerous fluid-filled vesicles that coalesce and progress into ulcers before they heal. These ulcers are usually extremely painful. Recurrence is common. Oesophageal or genito-anal ulcers that persist longer than one month constitutes an AIDS defining condition. The diagnosis is made on clinical grounds.
Treatment
Systemic antivirals such as acyclovir, valacyclovir or famcyclovir should be used for 7 days. Treatment may continue for 14 days if the response after 7 days is not sufficient. These drugs are virostatics, thus infections would most likely recur. Each episode should be treated, and maintenance therapy should only be reserved for extreme cases. 
CHRONIC DIARRHOEA
Clinical picture Chronic diarrhoea is debilitating to the patient. It is usually accompanied by loss of weight. Cryptosporidium parvum is the cause of chronic to fulminant diarrhoea in some cases. 14 
Special investigations
Chronic diarrhoea has many possible causes (which can be related to the level of immune suppression) and should be investigated for other possible infective pathogens before ascribing it to HIV. Stool microscopy and culture should be done on three occasions, as well as microscopy for parasites. A modified acid-fast stain on the stool is required to diagnose cryptosporidium and Isospora belli.
Treatment
The best practical approach would be to treat empirically for ten days with co-trimoxazole and metronidazole. Should there be no response to treatment, further investigations should be initiated and treatment tailored to the causative organisms isolated.
Salmonella typhi responds to ciprofloxacin for six weeks. Isospora belli would respond to cotrimoxazole, but a course of 4 weeks is indicated. Unfortunately no effective treatment exists for cryptosporidium infection. Antimotility drugs may be used, in conjunction with palliative care. Microsporidiosis responds to albendazole. In severe diarrhoea, attention should be paid to fluid maintenance, as well as possible potassium depletion.
KAPOSI'S SARCOMA
Clinical picture
Kaposi's sarcoma presents as discrete purple to brown-black patches on the skin that can infiltrate any mucocutaneous surface, including the gastrointestinal tract and lungs. Figure 7 demonstrated Kaposi's sarcoma of the gums. The skin lesions can be very unsightly and embarrassing for the patient. Larger lesions often ulcerate. Infiltration of lymph glands causes lymph oedema. Kaposi's sarcoma is regarded as AIDS defining, even if the CD4 count is above 200 cells/L. Infiltration beyond the skin, as well as a low CD4 count, would constitute poor prognostic features.
Diagnosis
A biopsy of the tissue is required for histology.
Treatment
The patient should be commenced on antiretrovirals, irrespective of the CD4 count. Local radiotherapy often gives excellent results. 14 Chemotherapy should be considered in combination with antiretrovirals if there be no response on antiretrovirals and bad prognostic features are present.
NON-HODGKIN'S LYMPHOMA (NHL)
Clinical picture
The patient may present with unilateral lymphadenopathy. The disease, however, is often atypical with extranodal or central nervous system involvement and the patient may present with systemic features (eg. fever or malaise) or central nervous system abnormalities (eg. confusion or localizing signs). Diagnosis Excision biopsy of a suspected lymph node. Aspiration of a lymph node cannot confirm the diagnosis. Stereotatic brain biopsy should only be undertaken if treatment can be offered to the patient.
Treatment
Histologically, NHL is usually a highgrade lesion and they require intensive chemotherapy regimen. Since this is an aggressive cancer, not all patients will benefit from the chemotherapy, and only candidates with a better possible outcome, should be offered chemotherapy. Chemotherapy should be used in conjunction with antiretrovirals. 14 CPD Questionnaire p.45
